Videos

Alicia Morgans, MD, MPH, discusses how to select the best treatment for patients with metastatic prostate cancer and the importance of monitoring them while on therapy.

The most common symptoms that present in patients with newly diagnosed myelofibrosis and variables that factor into initial treatment decisions.

Information provided by real-world data that is noted to be the most valuable to thoracic oncologists and others who manage patients with EGFR-mutant non–small cell lung cancer.

The role of signaling pathways, mutations, and alterations in the development of myelofibrosis (MF), and characteristics that distinguish primary MF from secondary MF.

CancerNetwork® sat down with C. Jillian Tsai, MD, PhD, at the 2021 American Society for Radiation Oncology to talk about the use of stereotactic body radiation therapy to treat breast and lung cancer.

CancerNetwork® sat down with C. Jillian Tsai, MD, PhD, at the 2021 American Society for Radiation Oncology to talk about why consolidative radiotherapy may be beneficial against oligoprogression in metastatic breast and lung cancer.

CancerNetwork® sat down with Hossein Borghaei, DO, MS, to talk about the rationale behind the TROPION-Lung04 trial using Dato-DXd plus durvalumab.

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about exciting trials in the head and neck space, including the phase 2 ORATER2 and phase 3 MC1675 trials.

CancerNetwork® spoke with Anthony W. Tolcher, MD, and Alexander I. Spira MD, PhD, about NEXT Oncology partnering with the Phase 1 Trials Program at Virginia Cancer Specialists to give patients another chance at treatment.

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss ongoing trials on treatment de-escalation and mitigating mucositis-related pain in head and neck cancer.

Concluding their discussion on newly diagnosed multiple myeloma, expert panelists consider treatment options for patients with high-risk disease.

A discussion on staging and grading criteria used in the assessment of acute graft-vs-host disease, and the potential role of biomarkers moving forward.

The potential impact that conclusions highlighted in a recent paper on postoperative MRD analysis in colorectal cancer may have on the management of patients with GI cancers.

Recommendations to help clinicians educate patients and caregivers about the risk of graft-vs-host disease following allogeneic transplantation.

Drs Cesar Perez and Victoria Meucci Villaflor consider questions raised by a recent study of tipifarnib in head and neck squamous cell carcinoma.

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss the potential role of gabapentin in head and neck cancer despite garnering negative results in oropharynx cancer.

Dr Morgans examines systemic treatment options for patients with metastatic castration-resistant prostate cancer.

An expert considers the role of BRCA1/2 mutations in metastatic prostate cancer.

Drs Lyudmila Bazhenova and Federico Albrecht comment on the pros and cons of real-world evidence to guide treatment decisions for patients with EGFR-mutant non–small cell lung cancer.

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss outcomes with gabapentin compared with opioids for increasing quality of life and decreasing treatment-related pain in oropharyngeal cancer.

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about using prophylactic gabapentin for those receiving chemoradiotherapy for oropharyngeal cancer.

John Kirkwood, MD, PhD, gives his opinion on duration of treatment for patients with melanoma.

Dr John Kirkwood explores the idea of taking drug holidays during melanoma treatment and whether it is helpful or harmful.

Brian Rini, MD, discussed abstracts presented during the 2021 ESMO Congress that will have an immediate impact on prostate cancer.

Experts Alexander Spira, MD, PhD, FACP, and D. Ross Camidge, MD, PhD, highlight the importance of global registries before sharing their closing thoughts on NRG1 fusions and the future treatment landscape of lung cancer.

Shared insight on the evolving treatment landscape of transplant-ineligible newly diagnosed multiple myeloma.

Experts hold a discussion regarding the timing and onset of acute graft-vs-host disease and chronic graft-vs-host disease following allogeneic transplantation, and prophylactic strategies used to help protect patients.

Experts discuss differences between the clinical manifestations and symptoms of acute and chronic graft-vs-host disease.

Following presentation of a paper by Loupakis F, et al., Drs Liliana Bustamante and Richard Kim raise questions pertaining to the use of ctDNA as a biomarker when managing patients with metastatic colorectal cancer undergoing resection.

The significance of studying strategies that target HRAS mutations in head and neck squamous cell carcinoma.